Pharmaceuticals & Therapeutics

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.

With stronger Phase 2 data for its ATH434 drug and a healthy cash reserve, Alterity Therapeutics is preparing for a pivotal trial and seeking partners.

Tonix Pharmaceuticals' newly approved drug, TONMYA, offers a breakthrough for millions, using unique science to combat the chronic pain of fibromyalgia.

Lexicon Pharmaceuticals raised nearly $95 million to fund its drug pipeline, but the move sent its stock plunging as investors weighed future promise against immediate dilution.

After teetering on the brink, Poxel SA has secured court approval for a complex recovery plan, offering a lifeline for its innovative metabolic drug pipeline.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

Houston biotech PranaX has closed an oversubscribed $17M Series A, signaling strong investor faith in its exosome-based approach to redefining quality of life.

A groundbreaking implantable cell therapy shows consistent, positive results for a debilitating complication of Crohn's disease, paving an expedited path to market.

With its acquisition offer falling short of a majority, Cycle Pharma extends its tender for Applied Therapeutics, leaving the company's fate in the balance.

A new report warns US drug price controls could mirror Canada's struggles, delaying access to new medicines. Is America trading innovation for affordability?

A new center in China is using a novel drug and special policies to offer hope against NUT carcinoma, a rare and deadly cancer affecting the young.

A new partnership gives Texas small business employees free access to a clinically proven virtual program aimed at reversing Type 2 diabetes, not just managing it.

Enveric Biosciences raises $1.5M to advance its novel psychiatric drugs. Is this small cash infusion enough to propel its promising pipeline forward?

A landmark FDA decision allows Life Biosciences to test its epigenetic reprogramming therapy, ER-100, offering new hope for restoring sight in the blind.

As drug-resistant fungi pose a grave threat, SCYNEXIS presents promising data on SCY-247, a next-gen drug that could redefine the fight against infection.

A new study in Nature Medicine shows a fasting-mimicking diet led to high remission rates in Crohn's patients, heralding a new era for 'Food as Medicine'.

With new funding, Stellular Bio is advancing an 'off-the-shelf' biologic therapy, offering new hope for Sjogren's patients and beyond.

Specialty chemical giant Lubrizol announces a multi-million-dollar investment to upgrade its Ohio HQ, boosting the local economy and its global reach.

A new partnership will test a novel drug in at-risk individuals, hoping to prevent Parkinson's disease before a diagnosis is ever made.

An oral drug for Huntington's disease shows early success, improving patient scores where a decline was expected, fueling hope for a breakthrough treatment.